Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors (Q34632923)

3 August 2017

Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors (English)

1 reference

3 August 2017

4

Keith T Flaherty

1 reference

3 August 2017

12

George Wilding

1 reference

3 August 2017

Anne M Traynor

1

1 reference

3 August 2017

Maureen Hewitt

2

1 reference

3 August 2017

Glenn Liu

3

1 reference

3 August 2017

Jason Clark

5

1 reference

3 August 2017

Steven J Freedman

6

1 reference

3 August 2017

Boyd B Scott

7

1 reference

3 August 2017

Ann Marie Leighton

8

1 reference

3 August 2017

Patricia A Watson

9

1 reference

3 August 2017

Baiteng Zhao

10

1 reference

3 August 2017

Peter J O'Dwyer

11

1 reference

3 August 2017

13 April 2010

1 reference

Cancer Chemotherapy and Pharmacology

3 August 2017

1 reference

3 August 2017

67

1 reference

3 August 2017

305-314

1 reference

3 August 2017

2

1 reference

https://scigraph.springernature.com/pub.10.1007/s00280-010-1318-9

3 August 2017

0 references

cites work

Clinical experience with aurora kinase inhibitors: a review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3050703

Discovery and development of aurora kinase inhibitors as anticancer agents

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3050703

The topoisomerase I poison CPT-11 enhances the effect of the aurora B kinase inhibitor AZD1152 both in vitro and in vivo

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3050703

Dual degradation of aurora A and B kinases by the histone deacetylase inhibitor LBH589 induces G2-M arrest and apoptosis of renal cancer cells.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3050703

Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3050703

Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3050703

Molecular basis of drug resistance in aurora kinases

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3050703

Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3050703

Effects of the Aurora kinase inhibitor VX-680 on anaplastic thyroid cancer-derived cell lines

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3050703

Aurora kinases as anticancer drug targets

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3050703

Aurora kinase inhibitory VX-680 increases Bax/Bcl-2 ratio and induces apoptosis in Aurora-A-high acute myeloid leukemia

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3050703

Sorafenib in advanced clear-cell renal-cell carcinoma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3050703

The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3050703

Aurora-B/AIM-1 kinase activity is involved in Ras-mediated cell transformation.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3050703

Aurora-kinase inhibitors as anticancer agents

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3050703

VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3050703

Cre-loxP-controlled periodic Aurora-A overexpression induces mitotic abnormalities and hyperplasia in mammary glands of mouse models

7 July 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1318-9

Expression of Aurora kinases A and B in normal, hyperplastic, and malignant human endometrium: Aurora B as a predictor for poor prognosis in endometrial carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1318-9

Enhancement of radiation response in p53-deficient cancer cells by the Aurora-B kinase inhibitor AZD1152.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1318-9

Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1318-9

Frequent overexpression of aurora B kinase, a novel drug target, in non-small cell lung carcinoma patients

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20386909

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20386909

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Amplification of chromosomal region 20q13 in invasive breast cancer: prognostic implications

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20386909

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S00280-010-1318-9

1 reference

Dimensions Publication ID

3 August 2017

0 references

1 reference

3 August 2017

1 reference